Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fedratinib→

Fedratinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
936091-26-8
Molecular formula
C27H36N6O3S
Molecular weight
524.7 g/mol
Drug class
Janus kinase 2 (JAK2) inhibitortargeted antineoplastic kinase inhibitor
Mechanism of action
Inhibits JAK2, including wild-type and mutationally activated forms, and has activity against FLT3. This reduces JAK-STAT signalling implicated in myeloproliferative neoplasm pathogenesis.
Indications / reported uses
  • Treatment of adults with intermediate-2 or high-risk primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera or post-essential thrombocythaemia) under the current product label

Sources: US DailyMed — INREBIC (fedratinib) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fedratinib Environmental Risk Assessment (ERA) (the Fedratinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.